The Hong Kong Polytechnic University
polyu.edu.hkTotal trials
611
Active
202
Phase 3
1
Total enrollment
82,103
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Atropine 0.05% | — | — | — | — | — | 1 | |
| Standard prophylactic medication | — | — | — | — | — | 1 | |
| tDCS & cognitive behavioral programme with home-based physical training | — | — | — | — | — | 1 | |
| Low dose atropine | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
- 2026-05-30
- 2026-12
- 2026-12
Top conditions
- Stroke60
- Myopia34
- Dementia23
- Depression14
- Healthy12
- Parkinson Disease10
- Chronic Pain9
- Insomnia9
Frequently asked questions about The Hong Kong Polytechnic University
- How many clinical trials does The Hong Kong Polytechnic University have on ClinicalTrials.gov?
- The Hong Kong Polytechnic University is listed as the lead sponsor on 611 clinical trials in ClinicalTrials.gov, 202 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The Hong Kong Polytechnic University's trials are in Phase 3?
- 1 of The Hong Kong Polytechnic University's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does The Hong Kong Polytechnic University focus on?
- The Hong Kong Polytechnic University's most-studied conditions on ClinicalTrials.gov are Stroke, Myopia, Dementia, Depression, Healthy.
- When are The Hong Kong Polytechnic University's next clinical trial readouts?
- The Hong Kong Polytechnic University has 4 upcoming primary-completion readouts tracked here; the soonest is “Tai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration”, expected around 2025-12-31.